Literature DB >> 12153168

T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.

M Reiser1, A Josting, M Soltani, P Staib, B Salzberger, V Diehl, A Engert.   

Abstract

T-cell NHL represent 10-15% of all malignant lymphomas making systematic prospective clinical trials difficult. Therefore, the prognostic significance of the T-cell phenotype has been a matter of controversy in recent years. In a retrospective analysis of 681 patients (pts) with NHL accrued from 1992 to 1997 at a single institution, 66 patients with T-cell NHL were identified. According to the REAL classification, histologies were as follows: 28 peripheral T-cell lymphomas (PTCL), 19 large cell anaplastic lymphoma (LCAL), 12 precursor lymphoblastic lymphoma (Lb), and seven AILD. Multiagent anthracycline containing regimens were used as initial therapy in 91% of cases. T-cell NHL represent 9.8% of all NHL patients at our institution accrued over a 6-year period. Overall response rate was 76%, 21% had progressive disease and 3% died during first line treatment. Mean overall survival (OS) was 8.22 +/- 0.94 years. There was a significant difference in OS between the four different histological subgroups (log rank P=0.0288). LCAL: mean OS 11.05 +/- 1.55 years (95% CI 8.00-14.09); LB: mean OS 7.09 +/- 1.40 years (95% CI 4.33-9.84); PTCL: mean 6.62 +/- 1.17 years (95% CI 4.33-8.90); AILD: 1.54 +/- 0.44 years (95% CI 0.67-2.40). OS was also significantly different for patients classified according to the International Prognostic Index (IPI)-score (log rank P = 0.002). Mean OS for patients with low risk, intermediate low risk, intermediate high risk and high risk was 10.46 +/- 1.02, 6.46 +/- 1.79, 4.50 +/- 1.20 and 1.15 +/- 0.46 years, respectively. Univariate analysis (log-rank test) for prognostic factors also revealed elevated LDH, B-symptoms and extranodal involvement as significant factors for OS. The presence of bulky disease (>7.5 cm), advanced stage III/IV and bone marrow involvement did not influence OS. In conclusion, it is evident that histological subtype and IPI-score have a strong prognostic impact on OS in pts with T-cell NHL. Thus, the distribution of risk factors in patients with T-cell NHL may be more important for OS than T-cell histology per se.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153168     DOI: 10.1080/10428190290016926

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

2.  Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Authors:  Mei Dong; Xiao-Hui He; Peng Liu; Yan Qin; Jian-Liang Yang; Sheng-Yu Zhou; Sheng Yang; Chang-Gong Zhang; Lin Gui; Li-Qiang Zhou; Yuan-Kai Shi
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

3.  A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.

Authors:  Abeer N Abouyabis; Pareen J Shenoy; Rajni Sinha; Christopher R Flowers; Mary Jo Lechowicz
Journal:  ISRN Hematol       Date:  2011-06-16

4.  Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.

Authors:  Yuna Lee; Keun-Wook Lee; Jee-Hyun Kim; Soo-Mee Bang; Jong Seok Lee; Byeong-Bae Park; Won Seok Kim; Cheolwon Suh; Jung Hun Kang; Baek Yeol Ryoo; Jae Hoon Lee; Dong Bok Shin
Journal:  Korean J Intern Med       Date:  2008-03       Impact factor: 2.884

5.  The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.

Authors:  R Briski; A L Feldman; N G Bailey; M S Lim; K Ristow; T M Habermann; W R Macon; D J Inwards; J P Colgan; G S Nowakowski; M S Kaminski; T E Witzig; S M Ansell; R A Wilcox
Journal:  Blood Cancer J       Date:  2014-05-30       Impact factor: 11.037

6.  Primary oral non-Hodgkin's lymphoma - A clinicopathologic study with immunohistochemical analysis.

Authors:  Dominic Augustine; Bala Sekar; R Thiruneervannan; Murali Sundhar; Donga Vijay Kumar Reddy; Shankar Gouda Patil
Journal:  J Int Soc Prev Community Dent       Date:  2014-11

Review 7.  T-cell lymphomas, a challenging disease: types, treatments, and future.

Authors:  Helen Ma; Maher Abdul-Hay
Journal:  Int J Clin Oncol       Date:  2016-10-14       Impact factor: 3.402

8.  Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report.

Authors:  Yudi Xiong; Lei Yang; Jing Dai; Fuxiang Zhou; Yunfeng Zhou
Journal:  J Med Case Rep       Date:  2020-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.